Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …
treatment, but current decision-making procedures have limited accuracy. In this study, we …
[HTML][HTML] Progress and challenges of predictive biomarkers for immune checkpoint blockade
Y Lei, X Li, Q Huang, X Zheng, M Liu - Frontiers in Oncology, 2021 - frontiersin.org
Over the past decade, immune checkpoint blockade (ICB) therapy has revolutionized the
outlook for oncology with significant and sustained improvement in the overall patient …
outlook for oncology with significant and sustained improvement in the overall patient …
[HTML][HTML] Network-based machine learning approach to predict immunotherapy response in cancer patients
Immune checkpoint inhibitors (ICIs) have substantially improved the survival of cancer
patients over the past several years. However, only a minority of patients respond to ICI …
patients over the past several years. However, only a minority of patients respond to ICI …
A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade
Immune checkpoint blockade (ICB) is efficacious in many diverse cancer types, but not all
patients respond. It is important to understand the mechanisms driving resistance to these …
patients respond. It is important to understand the mechanisms driving resistance to these …
[HTML][HTML] Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
M Zheng - Journal for immunotherapy of cancer, 2022 - ncbi.nlm.nih.gov
Background Recently, the US Food and Drug Administration (FDA) has approved immune
checkpoint blockade (ICB) for treating cancer patients with tumor mutation burden (TMB)> …
checkpoint blockade (ICB) for treating cancer patients with tumor mutation burden (TMB)> …
[HTML][HTML] Recurrent somatic mutations as predictors of immunotherapy response
Immune checkpoint blockade (ICB) has transformed the treatment of metastatic cancer but is
hindered by variable response rates. A key unmet need is the identification of biomarkers …
hindered by variable response rates. A key unmet need is the identification of biomarkers …
Mutational landscape and sensitivity to immune checkpoint blockers
RM Chabanon, M Pedrero, C Lefebvre… - Clinical Cancer …, 2016 - AACR
Immunotherapy is currently transforming cancer treatment. Notably, immune checkpoint
blockers (ICB) have shown unprecedented therapeutic successes in numerous tumor types …
blockers (ICB) have shown unprecedented therapeutic successes in numerous tumor types …
[PDF][PDF] Profiling of immune features to predict immunotherapy efficacy
Immune checkpoint blockade (ICB) therapies exhibit substantial clinical benefit in different
cancers, but relatively low response rates in the majority of patients highlight the need to …
cancers, but relatively low response rates in the majority of patients highlight the need to …
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Checkpoint blockade-based immunotherapy offers new options and powerful weapons for
the treatment of cancer, but its efficacy varies greatly among different types of cancer and …
the treatment of cancer, but its efficacy varies greatly among different types of cancer and …
Genomics-and transcriptomics-based patient selection for cancer treatment with immune checkpoint inhibitors: a review
KK Dijkstra, P Voabil, TN Schumacher… - JAMA oncology, 2016 - jamanetwork.com
Importance Checkpoint blockade therapy targeting cytotoxic T-lymphocyte–associated
antigen 4 (CTLA-4) and the programmed cell death protein 1 pathways (PD-1/PD-L1) have …
antigen 4 (CTLA-4) and the programmed cell death protein 1 pathways (PD-1/PD-L1) have …